Schulte Reinhard W, Wroe Andrew J
Department of Radiation Medicine, Translational Research, Loma Linda University Medical Center, Loma Linda, CA, 92354, USA.
Transl Cancer Res. 2012 Oct 1;1(3):184-195. doi: 10.3978/j.issn.2218-676X.2012.10.07.
Charged particle beam therapy has been used for almost 60 years. During the initial 40 years, the medical use of protons and heavy ions was explored at accelerator laboratories in a limited number of patients and for a limited number of cancerous and non-cancerous disease conditions. After the development of computed tomography and 3D treatment planning, it was time to move charged particle therapy into the clinical realm. This happened in October 1991 when an ocular melanoma patient became the first patient to be treated at Loma Linda University Medical Center in California. Due to the increased awareness of the advantages of charged particle therapy and promising results of single-institution experiences, one currently observes a phase of rapid expansion of proton treatment centers throughout the world. A few of these centers are combined proton/carbon ion facilities. It is very important that the technological evolution of charged particle therapy will continue during this phase of clinical expansion to ensure that the increasing number of patients exposed to therapeutic charged particles will benefit most from the advantageous dose distributions that these particles afford. This report will give an overview of translational research activities related to planning and verification of proton therapy in which the authors have been involved for a number of years. While our activities focus on protons, these developments are to a large degree also applicable to carbon ion therapy.
带电粒子束治疗已经应用了近60年。在最初的40年里,质子和重离子的医学应用在加速器实验室中针对有限数量的患者以及有限数量的癌症和非癌症疾病状况进行了探索。在计算机断层扫描和三维治疗计划发展之后,是时候将带电粒子治疗引入临床领域了。这发生在1991年10月,一名眼黑色素瘤患者成为加利福尼亚州洛马林达大学医学中心接受治疗的首例患者。由于对带电粒子治疗优势的认识不断提高以及单机构经验取得的令人鼓舞的结果,目前全世界正处于质子治疗中心快速扩张的阶段。其中一些中心是质子/碳离子联合设施。在临床扩张阶段,带电粒子治疗的技术发展将持续下去,这一点非常重要,以确保越来越多接受治疗性带电粒子照射的患者能够从这些粒子所提供的有利剂量分布中最大程度地受益。本报告将概述与质子治疗计划和验证相关的转化研究活动,作者多年来一直参与其中。虽然我们的活动主要集中在质子方面,但这些进展在很大程度上也适用于碳离子治疗。